Efficacy and safety of a single‐tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV‐1‐infected subjects on nonnucleoside reverse transcriptase inhibitor‐containing first‐line antiretroviral therapy in Pune, India

Lignende værker

• Formulation development and optimization of Lamivudine 300 mg and Tenofovir Disoproxil Fumarate (TDF) 300 mg FDC tablets by D-optimal mixture design
  af: Tibalinda, Prosper, et al.
  Udgivet: (2016)
• Simultaneous Spectrophotometric Estimation of Tenofovir Disoproxil Fumarate and Lamivudine in Three Component Tablet Formulation Containing Efavirenz
  af: Sharma, R., et al.
  Udgivet: (2010)
• Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in Pune, Western India
  af: Dravid, Ameet, et al.
  Udgivet: (2019)
• Two treatment strategies for management of Neurosymptomatic cerebrospinal fluid HIV escape in Pune, India
  af: Dravid, Ameet N., et al.
  Udgivet: (2020)
• RP-HPLC method for simultaneous estimation of tenofovir disoproxil fumarate, lamivudine, and efavirenz in combined tablet dosage form
  af: Bhavsar, Dhara S., et al.
  Udgivet: (2012)